Instant labeling of therapeutic cells for multimodality imaging

Hossein Nejadnik1#, Kyung Oh Jung2#, Ashok J. Theruvath1,3#, Louise Kiru1, Anna Liu4, Wei Wu1, Todd Sulchek4, Guillem Pratx2, Heike E. Daldrup-Link1,5##

1. Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, CA, 94305, USA
2. Department of Radiation Oncology, Stanford University, CA, 94305, USA
3. Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
4. Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA
5. Department of Pediatrics, Stanford University, CA, 94305, USA

# These authors contributed equally.

## Corresponding author: Heike E. Daldrup-Link, Molecular Imaging Program at Stanford, Stanford University, 725 Welch Road, Stanford, CA 94304. Email: heiked@stanford.edu

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2019.08.22; Accepted: 2020.03.03; Published: 2020.05.15

Abstract

Autologous therapeutic cells are typically harvested and transplanted in one single surgery. This makes it impossible to label them with imaging biomarkers through classical transfection techniques in a laboratory. To solve this problem, we developed a novel microfluidic device, which provides highly efficient labeling of therapeutic cells with imaging biomarkers through mechanoporation.

Methods: Studies were performed with a new, custom-designed microfluidic device, which contains ridges, which compress adipose tissue-derived stem cells (ADSCs) during their device passage. Cell relaxation after compression leads to cell volume exchange for convective transfer of nanoparticles and nanoparticle uptake into the cell. ADSCs were passed through the microfluidic device doped with iron oxide nanoparticles and 18F-fluorodeoxyglucose (FDG). The cellular nanoparticle and radiotracer uptake was evaluated with DAB-Prussian blue, fluorescent microscopy, and inductively coupled plasma spectrometry (ICP). Labeled and unlabeled ADSCs were imaged in vitro as well as ex vivo in pig knee specimen with magnetic resonance imaging (MRI) and positron emission tomography (PET). T2 relaxation times and radiotracer signal were compared between labeled and unlabeled cell transplants using Student T-test with p<0.05.

Results: We report significant labeling of ADSCs with iron oxide nanoparticles and 18F-FDG within 12±3 minutes. Mechanoporation of ADSCs with our microfluidic device led to significant nanoparticle (> 1 pg iron per cell) and 18F-FDG uptake (61 mBq/cell), with a labeling efficiency of 95%. The labeled ADSCs could be detected with MRI and PET imaging technologies: Nanoparticle labeled ADSC demonstrated significantly shorter T2 relaxation times (24.2±2.1 ms) compared to unlabeled cells (79.6±0.8 ms) on MRI (p<0.05) and 18F-FDG labeled ADSC showed significantly higher radiotracer uptake (614.3 ± 9.5 Bq / 1×10^4 cells) compared to controls (0.0 ± 0.0 Bq/ 1×10^4 cells) on gamma counting (p<0.05). After implantation of dual-labeled ADSCs into pig knee specimen, the labeled ADSCs revealed significantly shorter T2 relaxation times (41±0.6 ms) compared to unlabeled controls (90±1.8 ms) (p<0.05).

Conclusion: The labeling of therapeutic cells with our new microfluidic device does not require any chemical intervention, therefore it is broadly and immediately clinically applicable. Cellular labeling using mechanoporation can improve our understanding of in vivo biodistributions of therapeutic cells and ultimately improve long-term outcomes of therapeutic cell transplants.

Key words: mechanoporation, microfluidic device, iron oxide nanoparticles, 18F-FDG, in vivo cell tracking

Introduction

Autologous cell therapies for repair of degenerative joint diseases typically involve harvest of therapeutic cells, such as mesenchymal stromal cells (MSC) or adipose tissue-derived stem cells...
(ADSCs), and transplantation in one single surgery[1, 2]. Labeling the therapeutic cells with imaging biomarkers enables in vivo cell tracking with medical imaging technologies and early detection of complications of the engraftment process, such as cell death and cell loss from the transplant site[3-7]. Specifically, 18F-fluorodeoxyglucose (FDG) labeling can be used to quantify ADSC delivery and engraftment in the target tissue with positron emission tomography (PET), and nanoparticle labeling can be used for long-term evaluations of graft retention with magnetic resonance imaging (MRI).

However, until now, the only ways to label ADSCs for in vivo imaging have required manipulation of the cells in the laboratory. Upon extraction, the cells had to be incubated with contrast agents for several hours, washed, centrifuged and then transplanted[4, 8]. These manipulations are problematic for clinical translation because they could lead to cell sample contamination[9] or alterations in cell biology[10-12]. Most transfection agents, which are needed to shuttle imaging agents into stem cells, are not FDA-approved[13], may induce toxic effects[14-17] or alter stem cell biology[18]. In addition, ADSC labeling procedures in the laboratory take too long. In a clinical setting, ADSCs are harvested and transplanted within one surgery. To solve these problems, we developed a new technique for ADSC labeling based on simple passage of harvested cells through a novel microfluidic device, which provides instant labeling through cell compression and convective transfer of imaging biomarkers. This allows for ADSC harvest, isolation, microfluidic device passage, imaging biomarker labeling and transplantation in one session (Figure 1). Previous studies have shown that cell compression can be used for delivery of a wide range of molecules into different types of cells via diffuse delivery through transient membrane pores[19-21]. However, to our knowledge nobody has investigated instant stem cell labeling using cell compression and convective transfer of clinically available contrast agents. Tracking the biodistribution of therapeutic cells can improve our understanding of tissue engraftment and regeneration processes and facilitate early interventions in case of complications[22-25].

The purpose of our study was to test the ability of this new microfluidic device to label therapeutic cells within 15 minutes or less such that the labeled cells can be detected with MRI and PET.

Materials and Methods

Microfluidic device design and production.

We designed a customized microfluidic device for this project, with one inlet, five mechanoporation channels and one outlet. The mechanoporation channels contained chevron ridges with a gap size of 9.6 µm to achieve approximately 40% compression of ADSCs processed through the device. The ridges were angled to clear cell aggregates and debris that would otherwise clog the device. A pilot study demonstrated that a five-channel device successfully processed 50 million cells in 10 minutes without clogging.

The microfluidic device was molded into polydimethylsiloxane (PDMS) using a reusable SU-8 mold. Multiple devices were formed with a 10:1 ratio of PDMS and crosslinking agent that was mixed and poured onto the SU-8 mold. The PDMS was then degassed under a light vacuum chamber and cured for 1 hr at 80°C. The PDMS was then peeled from the molds and inlets and outlets were punched using biopsy punches. The PDMS was then bonded to cleaned microscope glass slides using a plasma bonder (PDC-32G Harrick) followed by 1 hr bake at 80°C.

Imaging biomarkers.

To achieve labeling of therapeutic cells with imaging biomarkers, we doped the microfluidic device with ferumoxytol nanoparticles and 18F-FDG radiotracer. Ferumoxytol (Feraheme®, AMAG Pharmaceuticals Inc., Cambridge, MA, USA) is an iron supplement, which is FDA-approved for treatment of anemia in adult patients with renal insufficiency[26-30]. Due to its superparamagnetic properties, ferumoxytol can be used “off label” as a contrast agent for MRI[31]. Ferumoxytol consists of iron oxide nanoparticles, which have a mean hydrodynamic diameter of 30 nm, a Zeta potential of -24.4 ±9.32, an r1 relaxivity of 15 s⁻¹mM⁻¹ and an r2 relaxivity of 89 s⁻¹mM⁻¹ at 1.5T and 37°C, 40 Hz[32].

In addition, we used the radiopharmaceutical 18F-FDG, a glucose analogue used clinically for assessment of tissue metabolism with positron emission tomography[33]. Medical-grade 18F-FDG was obtained from the Stanford Radiochemistry Facility.

Adipose tissue-derived stem cells.

Adipose tissue-derived stem cells were harvested from knee joints of Goettingen minipigs, using established techniques in our lab[34]. Briefly, <1mm³ tissue samples from the infrapatellar fat pad were collected, placed in type I collagenase (1.5mg/ml, Sigma Aldrich) for dissociation, centrifuged and then cultured in adipose-derived stem cell specific media. The cultured cells were characterized with specific surface markers for ADSCs according to the International Society for Cell Therapy (ISCT)[35] criteria, including CD29, CD44, CD71, CD90, CD105/SH2, SH3 and the widely

http://www.thno.org
recognized stem cell marker STRO-1 with lack of CD31, CD45 and CD106.

**Iron oxide labeling efficiency.**

We and others previously showed that a cell load of at least 1 picogram Fe per cell is required for cell detection with MRI [36, 37]. We also noted that that a cell load of less than 10 pg Fe per cell does not impair chondrogenesis [3, 38, 39]. In a pilot study, we doped the microfluidic device with ferumoxytol at increasing concentrations of 1, 5, 10, 15 and 20 mg iron/ml, processed 1×10⁷ ADSCs through the device and determined the cellular iron uptake with inductively coupled plasma optical emission spectroscopy (ICP-OES). We found that a concentration of 10 mg iron/ml led to a cellular iron uptake between our target of 1-10 pg per cell. Therefore, further studies were done with a concentration of 10 mg iron/ml. We measured the cell processing time through the device for every experiment. We chose a flow rate of 0.5 ml/min, because it translates in a five-channel device to ~70 mm/s flow velocity in each channel. According to flow rate data from Liu et al. 70 mm/s should yield close to maximum volume change [40].

The viability of ADSCs before and after passage through the microfluidic device was tested with Trypan blue (Invitrogen) and the colorimetric Cell Counting Kit-8 (CCK-8, Sigma-Aldrich, St Louis, MO, USA), which uses a water-soluble tetrazolium salt to quantify the number of live cells by producing an orange formazan dye upon bio-reduction in the presence of an electron carrier. To evaluate the efficiency of the ferumoxytol labeling, 1×10⁷ ADSCs were labeled with 10 mg/ml FITC-Ferumoxytol and unlabeled ADSCs were used as control. The percentage of cells labeled with FITC-Ferumoxytol was quantified by flow cytometry analysis (BD FACS Aria Fusion sorter, BD Bioscience, San Jose, CA, USA).

Next, we investigated whether ferumoxytol labeled ADSCs could be detected with MRI. We labeled triplicate samples of 1×10⁶ ADSCs with ferumoxytol, using the microfluidic device. Ferumoxytol-labeled and unlabeled ADSCs were transferred to test tubes and underwent MR imaging on a 3T MR scanner (Signa HDxt, GE Healthcare, Milwaukee, Wisconsin), using a flex coil (GE Healthcare, Milwaukee, Wisconsin). MRI included proton density weighted (PD) fast spin echo (FSE) with fat saturation (repetition time (TR) = 2700 ms / echo time (TE) = 32 ms / flip angle (FA) = 110° / matrix size 192 x 192 / slice thickness (SL) = 1 mm / field of view (FOV) = 14 cm / acquisition time (TA) =16 min), and multi-echo spin echo (TR=1200 / TE = 10,20,30,40,50,60,70,80/ FA = 90/ matrix size 192 x 192/ SL = 1.1/ FOV = 14/ TA = 13 min) sequences.

To analyze the MRI data, we generated T₂-relaxation time maps using Osirix software (Pixmeo SARL, Bernex, Switzerland) and measured T₂-relaxation times of each implant by operator-defined regions of interest [3].

---

**Figure 1. Concept of instant ADSC harvest and labeling with imaging biomarkers.** (A) Therapeutic cells are harvested from the pre-patellar fat pad. (B) ADSCs, adipocytes and monocytes are isolated through collagenase digestion and centrifugation. (C) The harvested cells are passaged through a novel microfluidic device, which provides instant labeling through cell compression and convective transfer of imaging biomarkers. (D) The labeled cells are seeded in scaffold. (E) The labeled cells in scaffold are implanted into cartilage defects. The engraftment of the labeled cells can be tracked in vivo with clinical imaging technologies.
To compare mechanoporation and conventional ferumoxytol labeling, triplicates of 1×10⁶ ADSCs were co-incubated with FITC-conjugated ferumoxytol or ferumoxytol alone (10 mg Fe/ml) for 12 minutes. Cells were washed twice with phosphate buffered saline (PBS) to remove residual ferumoxytol and then stained for cell nucleus (DAPI), cytoskeleton (Phalloidin) and FITC-conjugated ferumoxytol. In addition, DAB-enhanced Prussian blue staining was performed.

**Cell radiolabeling efficiency.**

18F-FDG labeling provides a clinically translational approach for PET/MRI tracking of ADSCs. The efficiency of the labeling procedure was investigated for two approaches, microfluidics-based mechanoporation and conventional passive co-incubation. A single-cell suspension of ADSCs (5×10⁶) was mixed with medical-grade 18F-FDG (57 MBq/ml; 1 ml 18F-FDG [344 MBq] mixed with 2 ml FACS buffer [3x] and 3 ml PBS) and passed once through the microfluidic device (5 channels, flow rate 0.5 ml/min). We measured the cell processing time through the device for every experiment. Another batch of ADSCs (1×10⁶) was incubated with 18F-FDG (30 MBq/ml; 0.1 ml 18F-FDG [33 MBq] mixed with 1 ml glucose-free DMEM) for 12 min at 37°C. The labeled cells were washed twice with PBS to remove residual radioactivity and 5×10⁴ cells were transferred to a 24-well plate for PET imaging (Inveon D-PET, Siemens Preclinical Solutions, Knoxville, TN) using an acquisition time of 10 min and an energy window of 425-650 keV. Unlabeled ADSCs (5×10⁴) were used as control. After PET acquisition, the radioactivity per well was quantified by region of interest (ROI) analysis using the Inveon Research Workplace (IRW) software. Another set of 1×10⁶ labeled cells was measured using an automatic gamma counter (Hidex, Turku, Finland).

**Dual-modality imaging of therapeutic cells in pig knee joints.**

To evaluate, if the microfluidic device assisted mechanoporation procedure enables dual-modality imaging of therapeutic cells in pig knee joints, we doped the microfluidic device with 10 mg/ml Ferumoxytol and 74 MBq/ml 18F-FDG and processed quadruple samples of 1×10⁷ ADSCs through the device. An additional quadruple set of 1×10⁷ ADSCs was processed through a microfluidic device doped with PBS. The dual labeled (n=4) and unlabeled (n=4) cells were implanted into eight full-thickness cartilage defects in the distal femur of pig knee specimen. The therapeutic cell transplants were secured with fibrin glue (Evicel®, Ethicon, Somerville, NJ) (Figure 1D and E) and the joint capsule, muscles and skin were closed with sutures.

Pig knees underwent simultaneous PET/MRI after stem cell implantation, using a clinical 3T Signa PET/MR scanner (GE Healthcare, Milwaukee, Wisconsin) equipped with a flex coil (GE Healthcare, Milwaukee, Wisconsin). MRI included proton density weighted (PD) fast spin echo (FSE) with fat saturation (repetition time (TR) = 2700 ms / echo time (TE) = 32 ms / flip angle (FA) = 110º / matrix size 192 x 192 / slice thickness (SL) = 1 mm / field of view (FOV) = 14 cm / acquisition time (TA) =16 min), and multi-echo spin echo (1200/ 10,20,30,40,50,60,70,80/ 90/ 192 x 192/ 1.1/ 14/ 13) sequences. PET images were obtained with an acquisition time of 30 min and 3D time-of-flight ordered-subsets expectation-maximization reconstruction.

To analyze the MRI data, we generated T₂-relaxation time maps and measured T₂-relaxation times of each implant as described earlier. To analyze the PET dataset, we used the scanner specific software (Image QC, GE Healthcare, Milwaukee, Wisconsin) and measured MBq/ml for each implant by operator-defined regions of interest.

**Statistical analysis.**

All experiments were performed with cells from at least three donors and repeated at least three times. All quantitative parameters were compared between different experimental groups, using an unpaired student t-test and considering a p<0.05 to indicate statistical significance. Statistical analysis was performed using GraphPad Prism (version 6.0).

**Results**

**Instant labeling of ADSCs with ferumoxytol nanoparticles with a novel microfluidic device.**

Our prototype microfluidic device is shown in Figure 2. The device is composed of one inlet, one outlet and one or more mechanoporation channels, depending on the number of therapeutic cells and volume of the cell suspension to be processed. Each mechanoporation channel contains multiple ridges with a vertical gap size that is tailored to the size of the specific therapeutic cell type with the goal to achieve a cell compression by approximately 40%. Therefore, we created ridges with a gap size of 9.6 µm for ADSCs, which have a diameter of 13-17 µm. ADSCs flow through the mechanoporation channel and pass under the ridges where they undergo rapid compression and lose some intracellular volume. After each ridge compression and volume loss event, the cells recover in shape and volume, causing the cell to uptake surrounding fluid and molecules (Figure
2C). The cell volume loss and recovery behavior leads to a transient increase in cell membrane permeability and intracellular uptake of target molecules by convective fluid transport [40]. The mean nanoparticle labeling time was 12 ± 3 minutes. We confirmed cellular uptake of FITC-labeled ferumoxytol by ADSCs with fluorescence microscopy (Figure 3A) and DAB-enhanced Prussian blue staining (Figure 3B).

Fluorescence activated cell sorting showed greater than 95% ADSC labeling efficiency (Figure 3C). ADSCs processed through the microfluidic device doped with ferumoxytol (10 mg Fe/ml) showed significant nanoparticle uptake (1.07 ± 0.05 pg per cell) compared to controls (0.12 ± 0.002 pg per cell), as determined by inductively coupled plasma optical emission spectroscopy (ICP-OES) (Figure 3D). The viability of microfluidic device processed and unprocessed ADSCs, as measured by Trypan blue staining, was not significantly different (Figure 3E). Transmission electron microscopy (TEM) showed iron oxide nanoparticles in secondary lysosomes (Figure S1). By comparison, conventional co-incubation of ADSCs with FITC-conjugated ferumoxytol or ferumoxytol alone (10 mg Fe/ml) for 12 minutes did not show detectable uptake into ADSCs by fluorescent imaging or DAB-enhanced Prussian blue staining, respectively (Figure S2).

Figure 2. Microfluidic device for instant cell labeling with imaging biomarkers. (A) Setup of a prototype microfluidic device with one inlet and one outlet. (B) Phase contrast image (corresponds to black box in E) of one channel of the microfluidic device with multiple ridges (C) Schematic cross-sectional view of therapeutic cells undergoing repeated compression under the ridges and expansion/relaxation after passing the ridges. The relaxation state leads to a transient increase in cell membrane permeability with convective uptake of nanoparticles and radiotracers. (D) Image of the silicon wafer used to fabricate the microfluidic devices. Image of (E) the 5-channel and (F) 1-channel microfluidic device mold for large and small cell samples.
Figure 3. Instant labeling of ADSCs with ferumoxytol nanoparticles using the novel microfluidic device. (A) Fluorescence microscopy of ADSCs before (unlabeled) and after (labeled) processing through the microfluidic device doped with FITC-conjugated ferumoxytol (10 mg Fe/ml). Labeled ADSCs demonstrate green fluorescent signal in the cytoplasm, confirming accumulation of ferumoxytol nanoparticle uptake (blue represents DAPI, red represents a phalloidin probe which selectively stains F-actin cytoskeleton and green represents FITC-conjugated ferumoxytol). (B) DAB-enhanced Prussian blue staining shows brown precipitation (arrow heads) in the cytoplasm of ADSCs, consistent with cellular accumulation of ferumoxytol nanoparticles. (C) Flow cytometry analysis of ADSCs demonstrates more than 95% labeling efficiency. (D) Iron content of ferumoxytol labeled cells, as determined by inductively coupled plasma optical emission spectroscopy shows significantly higher cellular iron uptake of ferumoxytol labeled cells compared to unlabeled controls (p < 0.0001). (E) Trypan blue assay demonstrated no significant difference in cell viability of ferumoxytol labeled cells compared to unlabeled controls. All quantitative data represent mean data ± SEM of three cell samples per experimental group; p < 0.05; unpaired t test.

Further in vitro validation studies revealed that dual labeling had no effect on the migration (Figure S4), proliferation (Figure S5), immunomodulation (Figure S6) and differentiation (Figure S7) of ADSCs. The labeling efficiency of iron oxide nanoparticles with different physiochemical properties (ferumoxytol, ferucarbotran, molday ION evergreen) was compared. Uptake of the positively charged nanoparticle; molday ION evergreen was higher in ADSCs compared to uptake of the negatively charged iron oxide nanoparticles (Figure S8). Due to our interest in developing a stem cell labeling approach that is translatable, ferumoxytol was used in subsequent experiments because it is an FDA approved nanoparticle.

**Microfluidic device assisted cell labeling enables cell detection with MRI and PET.**

Imaging can non-invasively and quantitatively assess the distribution of stem cells following autologous transfer. Next, we demonstrated that microfluidics-based mechanoporation can be used to label stem cells simultaneously with ferumoxytol nanoparticles and 18F-FDG for sequential or combined MRI and PET imaging. While many biomarkers are available to label stem cells, ferumoxytol nanoparticles and 18F-FDG were selected for this project in anticipation of future clinical translation. Ferumoxytol is FDA approved as an iron supplement and can be used “off label” as a contrast agent for MRI. 18F-FDG is the standard radiotracer for clinical PET imaging, and its use for labeling stem cells is well documented [41, 42]. However, conventional cell labeling relies on active transport of ferumoxytol nanoparticles or 18F-FDG by cells and thus requires long incubation times (30-60 min). Here, we investigate microfluidic device assisted mechanoporation as a new approach for instant intraoperative labeling of autologous stem cells.

We doped the microfluidic device with ferumoxytol (10 mg Fe/ml) and 18F-FDG (57 MBq/ml) and processed a suspension of ADSCs (5×10^6 cells/ml) through the device. Triplicate samples of 1×10^6 processed cells and unprocessed controls were transferred to Eppendorf test tubes and underwent MR imaging on a 3T clinical MR scanner (Signa HDxt, GE Healthcare, Milwaukee, Wisconsin). T2-weighted fast spin echo sequences showed a marked hypointense (dark) signal enhancement of ferumoxytol-labeled cells compared to unlabeled controls (Figure 4A). These findings were quantitatively confirmed by significantly shorter T2 values of ferumoxytol-labeled ADSCs (24.2 ± 2.1 ms / 1×10⁶ cells) compared to unlabeled ADSCs (79.6 ± 0.8 ms / 1×10⁶ cells) (Figure 4B). A colorimetric cell viability assay found no significant difference in viability of ferumoxytol labeled and unlabeled cells (Figure 4C). Another set of labeled cells were dispensed in 24-well plates (5×10^4 cells/well) and imaged using a preclinical PET scanner (Inveon D-PET, Siemens, Knoxville, TN). 18F-FDG-labeled ADSCs demonstrated strong radiotracer signal on PET images while unlabeled ADSCs showed no detectable radiotracer signal (Figure 4D). These findings were quantitatively confirmed by gamma counting (Figure 4E), which
revealed that $^{18}$F-FDG-labeled ADSCs had significantly higher radioactivity (614.3 ± 9.5 Bq / $1\times10^4$ cells) than unlabeled ADSCs (0.0 ± 0.0 Bq / $1\times10^4$ cells). Cell viability was not significantly affected by the radiolabeling procedure (Figure 4F).

Mechanoporation-based radiolabeling was compared with conventional cell labeling (passive co-incubation). Most cells, including stem cells, express glucose transporters (GLUT) on their surface to satisfy their glucose requirements. $^{18}$F-FDG is a known substrate for several GLUTs and it is actively imported by most cell types. However, GLUT expression may vary from sample to sample, leading to inconsistent labeling. Furthermore, GLUT-assisted labeling is too slow for intraoperative cell labeling. To compare microfluidic-device assisted mechanoporation and conventional $^{18}$F-FDG labeling, triplicate samples of $1\times10^6$ ADSCs were co-incubated with $^{18}$F-FDG and $5\times10^6$ ADSCs were processed through the microfluidics device. PET imaging revealed that cells labeled by mechanoporation had 63% higher uptake than cells labeled through conventional co-incubation (Figure S3A and S3B). These results were confirmed by gamma counting, which found that mechanoporation led to significantly higher $^{18}$F-FDG labeling of ADSCs (614.3 ± 9.5 Bq / $1\times10^4$ cells) compared with conventional co-incubation (376.6 ± 4.5 Bq / $1\times10^4$ cells; Figure S3C). There was no significant difference in cell viability between the two methods (Figure S3D).

**Microfluidic device assisted mechanoporation enables dual-modality imaging of therapeutic cells in pig knee joints.**

To ensure that the labeled cells can be detected in cartilage defects, an additional set of $1\times10^7$ dual-labeled ADSCs (with ferumoxytol and $^{18}$F-FDG) were implanted into artificially created cartilage defects of pig knee joint specimen, using previously established techniques [5, 8]. All specimens underwent integrated PET/MRI on a clinical PET/MRI scanner (Signa, GE Healthcare, Milwaukee, Wisconsin), using sagittal $T_2$-weighted sequences and simultaneous PET data acquisition (Figure 5).

Figure 4. Microfluidic device assisted cell labeling enables cell detection with PET and MR imaging. ADSCs were labeled with ferumoxytol nanoparticles and a separate set of cells was labeled with $^{18}$F-FDG, using microfluidic device-assisted mechanoporation. The cells were transferred to test tubes and scanned with clinical MRI and PET: (A) MRI shows marked hypointense (dark) $T_2$-signal of $1\times10^6$ ferumoxytol labeled ADSCs compared to unlabeled cells. (B) Corresponding quantitative data confirmed significant shortening of $T_2$ relaxation times of labeled ADSCs compared to unlabeled ADSCs ($p < 0.0001$). (C) Viability of ferumoxytol-labeled and unlabeled cells, measured with a Cell Counting Kit-8 (CCK-8) assay was not significantly different. (D) PET imaging demonstrates high PET signal of $^{18}$F-FDG-labeled ADSCs ($5\times10^4$) compared to unlabeled cells. (E) $^{18}$F-FDG uptake quantification by gamma counting confirms significantly higher radioactivity in $^{18}$F-FDG-labeled ADSCs compared to unlabeled ADSCs ($p < 0.0001$). (F) No significant difference in viability is observed between $^{18}$F-FDG-labeled and unlabeled cells. All data are shown as mean ± SEM of three cell samples per experimental group; $p < 0.05$; unpaired t test.
Dual-labeled ADSCs in cartilage defects of the distal femur showed a marked hypointense (negative) MRI signal, which enabled delineation of the therapeutic cell transplant. By comparison, unlabeled ADSCs could not be delineated from adjacent cartilage (Figure 5A). T2 relaxation time maps confirmed nanoparticle-induced shortening of T2-relaxation times in labeled ADSCs, with minimal T2 shortening of unlabeled ADSCs, (Figure 5B). Corresponding quantitative T2 relaxation times of labeled ADSC implants (41 ± 0.6 ms) were significantly decreased compared with unlabeled controls (90 ± 1.8 ms, p < 0.0001, Figure 5C). The same dual labeled cells demonstrated marked PET signal, while unlabeled ADSCs were not detectable with PET imaging (Figure 5D). Integrated PET/MR imaging added anatomical background information and enabled simultaneous detection of the nanoparticle and 18F-FDG signal of dual labeled cells (Figure 5E). Quantification of the PET signal confirmed significantly higher radioactivity in labeled implants (15.8 ± 3.5 MBq/ml) compared to unlabeled implants (0.1 ± 0.08 MBq/ml) (Figure 5F).

Discussion

Our results demonstrate that ADSCs can be labeled efficiently with a novel microfluidics device, which provides imaging biomarker uptake through mechanoporation. Previous studies have reported the use of mechanoporation for intracellular delivery of macromolecules for cell engineering applications[43]. However, to the best of our knowledge, microfluidics-assisted mechanoporation has not been explored for stem cell labeling and imaging applications. Our approach could be broadly applied for instant labeling of therapeutic cells with imaging biomarkers. This could facilitate in vivo cell tracking studies, improve our understanding of tissue regeneration processes, enable us to optimize new cell therapies and thereby, improve outcomes.

Previous approaches of mechanoporation for intracellular delivery of macromolecules included fluid shear loading [44], scrape loading [45], cavitation induction [46-48], microinjection [49], and nanoneedles [50, 51]. Common limitations of these techniques were low efficiency, impaired cell viability and poor throughput. Hallow et al. used fluid shear-forces in a microchannel system to load prostate cancer cells with macromolecules. However, labeling efficiency was approximately 30% and cell viability after labeling was 80% [44]. Matsumoto et al. used a nanoneedle array to deliver FITC-dextran into human embryonic kidney 293 cells and achieved a delivery efficiency of 45 ± 9% and for a relatively low cell
quantity of $\sim 10^5$ cells [50]. Shalek et al. used vertical nanowires to improve the delivery of biomolecules into primary mammalian cells. However, loading cells with biomolecules took up to one hour and some cell functions were impaired by the nanowires [51]. In our system, we labeled 50 million cells in a five-channel device with two different biomarkers within 15 minutes and achieved a labeling efficiency of 95% and less than 5% cell death. Our results are in line with a study by Liu et al. who reported that they were able to process 50 million cells within 10 minutes using a five-channel device [43]. While most of the results presented in their study were generated using single-channel devices, our study used multi-channel devices which increase throughput on a single chip by using multiple microchannels in parallel. In addition, we used microfluidic devices, tailored to ADSCs with a gap size of 9.6μm. The devices used in our study have been specifically designed and improved for rapid processing of stem cells for clinical translation.

Electroporation is an alternative approach which utilizes electric currents to transiently increase cell membrane permeabilities and thereby, deliver macromolecules to cells with high efficiency [52-54]. However, electroporation techniques impair cell viability and consequently, lead to cell loss. This is complicated in a clinical setting as it would require separation of viable and dead cells before their transplantation.

Establishing a balance between identifying a cellular iron load that is high enough to facilitate the detection of the iron labeled cells with MRI and low enough to prevent any effect on stem cell differentiation into chondrocytes is essential [3]. The orientation of the chevron ridges in our mecanoporation channels can be adjusted, therefore, we chose the orientation which resulted in significant MRI signal with minimum iron load, because excessive iron load can impair the chondrogenic differentiation of MSC [14]. Additionally, our studies and others have demonstrated that limited quantities of iron oxide in the cells will be incorporated in regular iron metabolism resulting in unimpaired chondrogenic differentiation of the labeled stem cells [3, 4, 55-57].

Our approach has the distinct advantage that it provides highly efficient biomarker labeling of therapeutic cells with minimal or absent effects on cell viability, migration, proliferation, differentiation and immunomodulation abilities, thereby enabling “one stop” cell harvest, labeling and transplantation procedures. Our method provides efficient and fast labeling of cells, compatible with the typical timeframe of a surgical procedure. Our study did not investigate the in vivo or ex vivo biodistribution of dual-labeled ADSCs, which is of high interest for longitudinal assessment of viability and activity of stem cells after labeling and transplantation. However, our future studies will investigate in vivo stem cell tracking in a large animal model and also evaluate tumor trafficking of chimeric antigen receptor (CAR) T-cells in a small animal model, using microfluidic-assisted labeling. Results from these future studies will provide more insight about in vivo viability and activity after labeling and will provide radiological-pathological correlations. Once validated, the new microfluidic device-based cell labeling approach could be immediately applied to study the engraftment of ADSC transplants in arthritic joints of patients in ongoing clinical trials. Once established, this microfluidics device could be also applied to label other therapeutic cell types, such as chondrocytes, MSC and T-cells, among others. Therefore, our results might have major and broad health care impact, can be readily translated to the clinic, provide a novel tool to monitor stem cell engraftment and ultimately, help improve long-term outcomes. Thus, we expect our new microfluidics device to spur on tissue regeneration research and stem cell imaging applications beyond our own research focus.

In summary, we reported a novel approach for rapid and efficient labeling of stem cells with a novel microfluidics device that enables imaging biomarker labeling and detection of transplanted cells with medical imaging technologies.

**Abbreviations**

ADSCs: adipose tissue-derived stem cells; FDG: $^{18}$F-fluorodeoxyglucose; GLUT: glucose transporters; ICP-OES: inductively coupled plasma optical emission spectroscopy; IRW: Inveon Research Workplace; ISCT: International Society for Cell Therapy; MRI: magnetic resonance imaging; MSC: mesenchymal stromal cells; PET: positron emission tomography; PDMS: polydimethylsiloxane; ROI: region of interest; TEM: Transmission electron microscopy.

**Acknowledgments**

The authors acknowledge support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant numbers 5R01AR054458-11 and R21AR075863. We thank Dawn Holley, Harsh Gandhi and Mehdi Khalighi from the PET/MRI Metabolic Service Center at the Lucas Imaging Center for help with PET/MRI scans. We thank Doreen Wu in the Stanford Animal Histology Services for help with preparation of histologic specimens. We also thank Guangchao Li in the
Environmental Measurements Facility (EMF) for help with ICP-OES. We also thank Christopher Reinhardt for providing us with the Molday iron oxide nanoparticle. We thank Carmel Chan for his help with confocal microscopy.

Author Contributions

H.D. and H.N conceived and designed the experiments, and wrote the manuscript. H.N. and A.J.T. performed the experiments, analyzed the data, acquired MRI images, and edited the paper. K.J. assisted in performing the experiments, editing the paper and labeling cells for PET imaging. L.K. assisted in performing experiments, analyzing data and editing the manuscript. A.L. and T.S. designed and produced the microfluidic devices. W.W. assisted in cell culture and labeling the cells. T.S. and G.P. edited the manuscript and provided overall guidance. All authors have given approval to the final version of the manuscript.

Supplementary Material


Competing Interests

The authors have declared that no competing interest exists.

References


